<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238444</url>
  </required_header>
  <id_info>
    <org_study_id>YZUC-001</org_study_id>
    <nct_id>NCT02238444</nct_id>
  </id_info>
  <brief_title>Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy</brief_title>
  <acronym>ESWA</acronym>
  <official_title>Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Warfarin Anticoagulation are effective and
      safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients with Hypersplenism
      after Laparoscopic Splenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After successful screening the cases of cirrhosis of liver irrespective of the etiology who
      have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will
      be recorded and the patient will be randomized into either interventional (warfarin) or
      control (aspirin) group. From postoperative day 3, patients in interventional (warfarin)
      group will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of
      2-3 for 1 year, patients in control (aspirin) group will receive oral Aspirin Enterie Ccoated
      Tablets 100mg qd for 1 year, and both groups will be along with five days of subcutaneous
      injection of Low Molecular Weight Heparin and three months of oral Dipyridamole. Every 3
      months the Doppler screening for the occurrence of portal vein thrombus (PVT) or
      spleno-mesenteric thrombosis will be done for all patients. Both groups will receive the
      therapy for one year irrespective of the Doppler findings in relation to portal vein thrombus
      occurrence. Then one year monitoring will be done in the both groups as per the primary or
      secondary outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of patients who will suffer from PVT or spleno-mesenteric thrombosis between oral anticoagulant Warfarin with dipyridamole group and oral Aspirin with dipyridamole group during the study period of 3 year from randomization</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will show improvement in Child Pugh (&gt;2 points)in both groups</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will show improvement in Model for End Stage Liver Disease (MELD)(&gt;4 points)in both groups</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will show decrease in hepatic decompensation defined as development of ascites, PSE, portal hypertensive bleeding, jaundice, spontaneous bacterial peritonitis, or systemic infection</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients who will suffer from hepatocellular carcinoma</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in both groups</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hypertension</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Status; Splenectomy</condition>
  <arm_group>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.</description>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <other_name>Warfarin Sodium</other_name>
    <other_name>Athrombine</other_name>
    <other_name>COUMADIN</other_name>
    <other_name>PANAWARFIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole</intervention_name>
    <description>From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.</description>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <other_name>Gardoxin</other_name>
    <other_name>Coribon</other_name>
    <other_name>Curantyl</other_name>
    <other_name>Dilaplus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.</description>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <other_name>Acenterine</other_name>
    <other_name>Acetard</other_name>
    <other_name>Acetophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Molecular Weight Heparin</intervention_name>
    <description>From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.</description>
    <arm_group_label>Warfarin with dipyridamole</arm_group_label>
    <arm_group_label>Aspirin with dipyridamole</arm_group_label>
    <other_name>Fraxiparine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical, radiological or histologic diagnosis of cirrhosis of any etiology

          -  Splenomegaly with secondary hypersplenism, Platelet count &lt; 50*10^9/L

          -  No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and
             angio-CT

          -  Informed consent to participate in the study

        Exclusion Criteria:

          -  Hepatocellular carcinoma or any other malignancy

          -  Hypercoagulable state other than the liver disease related

          -  DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs

          -  Base line INR &gt;2

          -  Child-Pugh grade C

          -  Recent peptic ulcer disease

          -  History of Hemorrhagic stroke

          -  Pregnancy

          -  Uncontrolled Hypertension

          -  Age&gt;75 yrs

          -  F2 varices with red whale marks or F3 varices

          -  Bleeding portal hypertension

          -  Human immunodeficiency virus (HIV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dou-Sheng Bai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo-Qing Jiang, MS</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ping Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Jie Jin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Medical College of Yangzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guo-Qing Jiang, MS</last_name>
    <phone>86-514-87373272</phone>
    <email>jgqing2003@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dou-sheng Bai, MD</last_name>
    <phone>86-514-87373275</phone>
    <email>bdsno1@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Medical College of Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luo-Jing Zhou, MD</last_name>
      <phone>86-514-87373037</phone>
      <email>luojing76@163.com</email>
    </contact>
    <investigator>
      <last_name>Dou-Sheng Bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>October 1, 2017</last_update_submitted>
  <last_update_submitted_qc>October 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Guo-Qing Jiang</investigator_full_name>
    <investigator_title>Master</investigator_title>
  </responsible_party>
  <keyword>Warfarin</keyword>
  <keyword>Portal Vein</keyword>
  <keyword>Anticoagulants</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Venous Thrombosis</keyword>
  <keyword>Splenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Hypersplenism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

